



Waters launches RUO LC-MS test method to advance infectious disease research

26 May 2021 | News

Waters developed the SARS-CoV-2 LC-MS Kit (RUO) in support of a coalition of academic, commercial and government research scientists

Waters Corporation has introduced a new RUO LC-MS test method to advance critical infectious disease research. Waters™ [SARS-CoV-2 LC-MS Kit \(RUO\)](#) uses an orthogonal analytical method that directly detects and quantifies SARS-CoV-2 Nucleocapsid (NCAP) peptides that initial studies have shown to yield highly accurate, quantitative results.

Waters developed the SARS-CoV-2 LC-MS Kit (RUO) in support of a coalition of academic, commercial and government research scientists. This coalition worked to develop an alternative test method on LC-MS platforms in support of the United Kingdom's National Health Service (NHS) Test & Trace program.

Their goal was to create a complementary, high-throughput screening method that would also use different reagents to help relieve strain on the PCR reagent supply chain.

In just 16 weeks, the research coalition went from development of the method in university labs to a translated LC-MS workflow – upon which the SARS-CoV-2 LC-MS Kit (RUO) is based.

The Waters SARS-CoV-2 LC-MS Kit (RUO) has been optimized on the [ACQUITY™ I-Class Plus System](#) and the Xevo TQ-XS System. It comes in an adaptable automation-friendly format with liquid handling protocols for the [Andrew[±] Pipetting Robot](#) on [OneLab™](#) Software.